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During the establishment  of the L5178Y cell tumor dormant state in DBA/2 mice, 
described  in  the  previous communication  (1),  mice develop a  strong cytolytic anti- 
tumor response  mediated  by peritoneal  T  cells.  Despite  this  cell-mediated  cytolytic 
(CMC) 1 activity, small  numbers  of tumor cells  persist  in clinically  normal  mice for 
prolonged periods. Termination of the dormant state is signaled by the appearance of 
overt  ascitic  tumors  and  this  occurs  most  frequently  when  CMC  is  no  longer 
demonstrable in the majority of clinically normal mice. 
The  outgrowth  of tumor  cells  at  the  end  of the  dormant  state  could  be  due  to 
changes in the antigenic  or malignant  properties  of the cells,  to waning host tumor 
suppressive activity, or to a combination of these. Phenotypic alterations within tumor 
cell populations during in vitro or in vivo exposure to an immune environment have 
been described in several experimental  systems (2-5). However, in at least one tumor 
dormant  system (6), cells emerging after long-term quiescence were found to exhibit 
properties  identical  to those cells used  to produce the dormant  state.  In this  system 
immunosuppressive measures released tumor cells from a dormant state and permitted 
their rapid outgrowth. 
Tumor dormancy differs from the slowly dividing tumor cell subpopulation by the 
presence of some form of restraint  on tumor cell growth. In the tumor dormant state, 
the tumors which eventually emerge must be progeny of the primary tumor, and not 
a newly transformed host cell. Both of these phenomena were demonstrated in Burkitt 
lymphoma by Fialkow et al. who found that early relapses were due to reappearance 
of original  malignant  clones  whereas  late  relapses  were  due  to  outgrowth  of new 
malignant cell lines (7). 
The  present  study  was  undertaken  to  determine  the  origin  and  growth  rate  of 
tumor cells which eventually emerge from the tumor dormant state. Various properties 
of original  and  emergent  L5178Y  cells  were  compared  to  understand  how  small 
numbers  of tumor cells  avoid  immune  lysis,  survive  in  an  immune environment  in 
vivo, and eventually emerge from the dormant state to form ascitic tumors. 
* Supported  by grants  18995 and  12504 awarded by the National Cancer Institute,  Department  of 
Health,  Education,  and Welfare, by the  National  Foundation--March of Dimes and  by Biomedical 
Research Support grant  1 SO7 RR-05414. 
1 Abbreviations used in  this paper: C',  complement;  CMC,  cell-mediated cytolysis; FITC,  fluorescein 
isothiocyanate; PC, peritoneal cell; PBS, phosphate-buffered saline; TAA, tumor-associated antigen. 
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Materials and Methods 
Mice.  DBA/2  female mice  (8  wk old)  were obtained  from  The Jackson  Laboratory,  Bar 
Harbor,  Maine.  Male  DBA/2  mice  (8  wk old)  were  obtained  from  Charles  River Breeding 
Laboratories, Wilmington, Massachusetts. 
Tumor  Cell  Lines.  DBA/2-derived  methylcholanthrene-induced  L5178Y  lymphoma  and 
P815-X2  mastocytoma  cells as  well as C57BL/6-derived benzanthracene-induced  EL-4 lym- 
phoma cells were obtained from Dr. Lionel Manson  of the Wistar Institute, Philadelphia,  Pa. 
Friend  leukemia  virus-transformed  DBA/2 erythroblasts  designated  clone 745  were obtained 
from the Genetic Mutant  Cell Repository, Camden,  N.J. All cell lines were maintained  by in 
vivo passage into susceptible animals and as suspension cultures in RPMI-1640  (Grand Island 
Biological Co.,  Grand  Island,  N.Y.)  supplemented  with  penicillin  (100  U/ml), streptomycin 
(100/xg/ml), glutamine (2 mM), and  15% fetal calf serum. 
Immunization of Tumor Recipients and Establishment of the Dormant State.  L5178Y lymphoma cells 
(1  X  106 cells) were implanted subcutaneously on the ventral surface of DBA/2 female mice. 
10 d  later the resultant  1-cm diameter nodules were surgically removed. After an additional  7 
d, all mice received an intraperitoneal challenge of 5  X  104 L5178Y cells. Control mice which 
were  immunized  but  not  challenged  were  free of isolatable  tumor  cells and  lived a  normal 
lifespan. 
Definitions.  Clinical  normalcy,  see  previous  communication  (1).  Original  L5178Y  tumor 
cells:  the  L5178Y  cells which  were  maintained  by  weekly  i.p.  passage  into  normal  DBA/2 
female mice are  referred  to  as  original  tumor  cells.  Original  L5178Y  cells were  used  in  all 
immunization and challenge protocols. Emergent L5178Y tumor cells: the tumor cells isolated 
from tumors which emerged in L5178Y cell immunized and challenged mice after a prolonged 
clinically normal period are referred to as emergent tumor cells. The emergent tumor cells used 
in this report  were obtained  from mice with tumor  burdens  exceeding 5  ×  108 ascitic tumor 
cells. 
Antisera.  Alloantisera against DBA/2 histocompatibility antigens was prepared as described 
in  the  previous  communication  (1).  Xenogeneic  anti-L5178Y  serum  was ~repared  in  New 
Zealand  White  rabbits  by  a  series  of eight  subcutaneous  injections  of  10  ascitic  passaged 
original L5178Y cells spaced at  10-d intervals.  1 wk after the final injection, the rabbits  were 
exsanguinated.  The  serum  was  inactivated  at  56°C  for  30  min  and  absorbed  with  DBA/2 
thymus  and  P815-X2  mastocytoma cells, a  DBA/2 cell line which  does not  cross-react  with 
L5178Y  cells in  CMC  assays  (data  not  shown).  The  resultant  absorbed  rabbit  anti-L5178Y 
(Ra-a-L5178Y)  serum  was  shown  to  possess  cytolytic activity against  L5178Y  cells but  not 
normal  DBA/2 thymocytes nor FLC-745 cells in complement-dependent  assays.  Anti-Thyl.2 
serum was obtained from Litton Bionetics, Kensington, Md. Fluorescein isothiocyanate (FITC) 
conjugated goat anti-rabbit  serum was obtained from Cappel Laboratories Inc., Cochranville, 
Pa. 
Karyotype Analysis.  Chromosome preparations were made as described by Miller et al. (8). In 
this comparison 32 original tumor cells and 28 emergent tumor cells were evaluated. 
CMC Assays.  All CMC assays were performed as described previously (1). 
Antibody-Dependent  Complement-Mediated Cytolysis Assays.  All  assays  were  performed  as  de- 
scribed previously (1). 
Cold Target Inhibition Assay.  The ability of original and emergent L5178Y cells to competi- 
tively inhibit  peritoneal cell (PC)  cytolytic activity against 51Cr-labeled original L5178Y cells 
was assayed by using a  modification of the cold target  inhibition assay of Ortiz de Landazuri 
and  Herberman  (9).  Briefly,  various  numbers  of  unlabeled  inhibitor  cells  were  added  to 
microtiter plate wells containing  106 immune PC and  104 51Cr-labeled original L5178Y cells. 
The  plates  were  incubated  for  4  h  at  37°C  after  which  supernates  were  collected  and 
radioactivity determined.  The  percent-specific lysis values were obtained  as  described  in the 
previous communication. The percent inhibition values were then calculated as follows: 
percent lysis of noninhibited  group -  percent lysis of inhibited group 
x  100. 
percent lysis of noninhibited group 
Quantitative Absorption Assay.  Various numbers of original and emergent L5178Y cells were 
compared  for  their  ability  to  absorb  cytolytic  antibody  from  Ra-a-L5178Y  sera  with  a K. J.  WEINHOLD,  D.  A.  MILLER,  AND E.  F. WHEELOCK  747 
modification of a previously described absorption procedure (10). Briefly, various numbers of 
absorbing cells, ranging from  1.25  ×  10  ~ to 3.20  ×  107, were incubated in 0.5 ml of a  1:20 
dilution of Ra-a-L5178Y sera at 5°C for 30 min with occasional shaking. Cells were pelleted by 
centrifugation at 450 g for 10 min. 0.1  ml of the resulting supernate was added to microtiter 
wells, followed by the addition of 5  ×  104 (0.05 ml) 5XCr-labeled original L5178Y  cells. The 
mixture was incubated at 5°C for  15 rain. 50 #1 of guinea pig complement was added to the 
wells and the reaction mixture was shaken vigorously and incubated at 37°C for 60 min. After 
incubation, the plates were spun at  150 g for  10 min, and 0.1-ml samples were removed and 
assayed for radioactivity. 
Indirect Immunofluorescence Assay.  Original and  emergent  L5178Y  cells  were  resuspended 
separately in phosphate-buffered saline (PBS) at a concentration of 5 ×  106 cells/ml. 0.1 ml of 
cells was incubated with 0.1 ml of various dilutions of absorbed rabbit anti-L5178Y serum for 
30 min at 5°C with constant agitation. The cells were washed three times with PBS and the 
pellet resuspended to 0.1 ml. 0.1 ml of a  1:10 dilution of FITC-labeled goat anti-rabbit serum 
was added and the mixture reincubated at 5°C for 30 min. After further washing with PBS, 
cells were placed on clean glass microscope slides and sealed with glass cover slips. Slides were 
examined at  × 930 magnification using an AO vertical illumination  microscope with an HB-50 
ultraviolet light source. 
Neuraminidase Treatment of Original and Emergent L5178 Y Cells.  Original and emergent L5178Y 
target  cells  were treated  with neuraminidase according to the procedure of Turianskyj and 
Gyenes (11). Briefly,  2  ×  106 cells were first labeled by incubation in medium containing 250 
/~Ci of Na251CrO4 for  45  min. After  labeling, cells  were  washed  twice  in  PBS  and  finally 
resuspended in 0.5  ml of PBS.  50 U  of streptococcal neuraminidase (obtained from Joseph 
Goldschmidt, Thomas Jefferson University) was added to the cell suspension, and the mixture 
was incubated at 37°C for 20 min. Cells incubated in buffer served as controls. After incubation, 
cells  were  washed  three  times  in  10  vol  of PBS  and  resuspended  in  medium  to  yield  a 
concentration of 1 ×  105 cells/ml. Susceptibility to lysis was determined in a 4-h CMC assay 
as described previously (1). 
Results 
Cytogenetic Analysis  of Emergent  Tumor Cells.  To determine whether the tumor cells 
which  emerged  in L5178Y  cell  immunized and challenged mice after  a  prolonged 
period of clinical normalcy were progeny of the tumor cells contained in the challenge 
inoculum rather than newly induced in the recipient host, we searched for abnormal 
chromosomal markers common to both original and emergent cells. In this analysis, 
a  tumor dormant state  was  established in male DBA/2  mice by using the  female 
derived original L5178Y cells, thereby permitting us to search also for a Y chromosome 
in the emergent tumor. An ascitic tumor emerging 218 d  after L5178Y cell challenge 
was selected for this comparison. 
The original tumor cell line had  an average of 72.3  chromosomes per cell, with 
most cells having 73 or 74. These included copies of normal chromosomes, as well as 
structurally altered, or marker chromosomes. The emergent tumor cells had a slightly 
greater average number of chromosomes per cell, 78.7, and a  somewhat wider range 
of chromosome numbers (62-93 compared to 61-75 for the original tumor cells). At 
least  nine of the  marker  chromosomes  seen  in  the  original tumor  cells  were  also 
present in the emergent tumor cells (Fig.  1). None of these marker chromosomes were 
seen  in  normal DBA/2  cells.  No  Y  chromosome was  seen.  Chromosomal  analysis 
therefore provides convincing evidence that the emergent tumor cells are progeny of 
the original L5178Y cell inoculum. 
Analysis of Growth Rate of Emergent  Tumor Cells.  Because the emergent tumor cells 
were shown to be progeny of the original cell inoculum, the properties of these two 
tumor  cell  isolates  were  studied  for  differences  which  could  be  responsible  for 748  COMPARISON OF  ORIGINAL AND  EMERGENT  L5178Y  CELLS 
FIG.  1.  Quinacrine-stained abnormal, or marker,  chromosomes  from the original tumor cells (left 
member of each pair)  and the emergent tumor cells (right  member of each pair).  Note that for each 
pair the banding patterns of the two chromosomes  are identical. 
TABLE  I 
In  Vivo Growth of Original and Emergent L5178Y Cells in Normal DBA/2 Mice 
Tumor cells* recovered  on  Mean day of tumor associ-  Inoculum  day 20  ated death~ (+  SD) 
5  >(  104 L5178Y  3.6  X  l0  s  (+0.3){}  24.4 (+ 1.4)§ 
(Original) 
5  X  104 L5178Y  3.2  X  l0  s  (:t:0.2)  27.2(+1.5) 
(Emergent) 
* Three mice from each group were killed 20 d after i.p. injection and the number of tumor 
cells in the peritoneal cell population was determined by end point dilution analysis  (see 
previous  communication). 
Each experimental group contained six mice. 
§ P >  0.1; not a significant difference  between original and emergent cells. 
emergence  from  the  dormant  state.  We  first  compared  the  in  vivo  growth  rate  of 
emergent  L5178Y cells with original L5178Y cells to determine whether the emergent 
cells were  a  slowly  dividing  subpopulation  of the  original  L5178Y  cells.  Groups  of 
normal age-matched  DBA/2  mice were inoculated i.p. with identical numbers of cells 
of both types and observed for both increases in numbers  of tumor cells and the times 
of tumor  associated  deaths. 
As seen  in Table  I, the  numbers  of tumor  cells present  in  the peritoneal  cavity 20 
d  after  an  inoculation  of  5  ×  104  original  or  emergent  L5178Y  cells  were  not 
significantly different,  suggesting that  both original and emergent  L5178Y  cells have 
nearly  equivalent  population  doubling  times  in  vivo.  There  was  also  no  significant 
difference  in  the  times  of tumor  associated  deaths  between  the  two  groups  of mice. 
Further  evidence  that  emergent  tumor  cells  were  not  merely  a  slowly  dividing 
subpopulation  of original  L5178Y  cells is provided by the rate of tumor  growth  seen 
in L5178Y immunized  and challenged mice after the termination of tumor dormancy. K. J.  WEINHOLD,  D.  A. MILLER, AND E.  F,  WHEELOCK 
TABLS II 
Susceptibility of Original and Emergent L5178 Y Cells to CMC 
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Target cells 
% Specific 51Cr release 
DBA/2 t~-L5178Y Effector PC* 




L5178Y (original)  83.5  79.6  85.2  93.6 
L5178Y (emergent)  30.1  35.9  33.7  91.4 
Significance  P < 0.001  P < 0.001  P < 0.001  P > 0.1 
* DBA/2 effector PC were obtained from L5178Y (original) immunized  mice 7 d after i.p. tumor cell 
challenge. For exp.  1, 2, and 3, origifial and emergent target cells were obtained from three different, 
original, and emergent tumorous mice, respectively. Cells were labeled with 5XCrO4 and utilized in 18-h 
cytolysis assays at an effector:target ratio of 100:1. 
C57BL/6 effector PC were obtained from mice immunized against DBA/2 cells by two i.p. injections of 
107 SPC spaced a week apart. PC were collected 7 d after the final injection and utilized in 18-h cytolytic 
assays at a 100:1 effector:target ratio. The target cells in this instance were the same as those used in exp. 
1. 
Emergent  tumors,  once detected at  the end of the tumor dormant  period, enlarged 
more rapidly, (average increase in total body weight of 2 g/d) than original L5178Y 
tumors growing in nonimmunized mice (0.4 g/d). 
Decreased Susceptibility  of Emergent  Cells  to  CMC In  Vitro.  The  L5178Y  cells which 
grew out  at the end of a  prolonged dormant  state were compared with the original 
L5178Y  cells to  detect  differences which  could  account  for  their  escape  from  dor- 
mancy.  For  this  comparison  three  sets  of original  and  emergent  L5178Y  cell  lines 
were established, each  line from  a  different tumor bearing mouse.  The  sets of cells 
were tested for susceptibility to CMC  by PC from tumor dormant mice. 
As  seen  in  Table  II,  all three  emergent  L5178Y  cell  lines were  significantly less 
susceptible than  the  original cells to  lysis by  peritoneal cells from  tumor  dormant 
mice.  However, the original and emergent  L5178Y  cells were equally susceptible to 
lysis by  alloimmune  PC,  indicating  that  the  decreased  lysis of emergent  cells  by 
syngeneic effectors was not due to a  physiologic nonlysable state of the cells. 
Examination  of Emergent  Cells for  the  Presence of an  Antigen  Mask.  The  equivalent 
susceptibility of original  and  emergent  L5178Y  cells  to  lysis by  alloimmune  cells 
suggested that antigen masking was not responsible for the decreased susceptibility of 
emergent cells to lysis by PC from tumor dormant mice. To investigate the possibility 
of antigen masking further, we measured expression of nontumor-associated antigens 
on original and emergent cell populations using serologic reagents. As shown inTable 
III, both cell lines were equally susceptible to lysis by anti-H-2  d  +  C' and anti-Thy 
1.2  +  C', suggesting that expression of these nontumor antigens was unaltered in the 
emergent  cell population.  We  next  treated  original and  emergent  cell populations 
with  neuraminidase.  As shown  in Table III, neuraminidase  treatment  did not  alter 
the  respective  susceptibilities  of  these  cells  to  CMC.  These  data  provide  strong 
evidence against antigen masking as a  mechanism  for the decreased susceptibility of 
emergent cells to lysis by tumor dormant PC. 
Stability  of Decreased Susceptibility of Emergent Cells to CMC during In Vitro Culture.  The 
decreased  susceptibility of emergent  cells  to  CMC  could  be  the  result  of in  vivo 
antigenic modulation.  To  evaluate antigenic modulation,  we  isolated L5178Y  cells 750  COMPARISON OF ORIGINAL AND  EMERGENT L5178Y  CELLS 
TABLE  III 
Comparison of Surface Cytolytic Target Antigen Expression on Original and Emergent L5178 Y Cells 
Treatment of  Dilution or con- 
target cells  centration  Cytolytic assay 
Specific 51Cr release 
from target cells 
Original  Emergent 
L5178Y  L5178Y 
Anti-H-2  d 
% 
1  : 1,000  C'-dependent*  81.1  79.2:~ 
1:2,000  "  63.5  58.6:~ 
1:4,000  "  39.9  39.6:~ 
1:8,000  "  19.7  20.5~ 
Anti-Thy 1.2  1:80  C'-dependent*  33.7  35.2:~ 
1:160  "  17.2  20.6:~ 
1:320  "  8.3  10.1:~ 
1  :  640  "  3.1  2.9:~ 
Neuraminidase  50 U/ml  Cell-mediated§  59.611  30.611 
Buffer  -  "  58.7  31.5 
* Original and emeragent L5178Y cells were labeled with 51Cr, washed, and incubated with various dilutions 
of either anti-H-2  serum or anti-Thyl.2 serum for 90 rain  in the presence  of guinea pig complement. 
Relative cell lysis was determined by the amount of 5aCr released. 
:1: P >  0.15, no significant  difference in lysis of original and emergent L5178Y cells. 
§ Original and emergent L5178Y cells were labeled with SlCr, washed and incubated either in buffer or in 
50 U of streptococcal  neuraminidase for 20 rain. After incubation, labeled cells were washed  three times 
in medium and incubated in the presence of day 7 tumor dormant PC in a 4-h CMC assay at an effector: 
target ratio of 100:1. CMC activity was determined by the amount of 51Cr released. 
]] P :> 0.15, no significant  difference between pre-and postneuraminidase treatment susceptibility  to CMC. 
from  a  tumor  emergent  mouse  and  cultured  the  cells  in  vitro  in  a  nonimmune 
environment  for various periods of time and  then  retested  their susceptibility  to lysis 
by immune  effector cells. We found that  the decreased susceptibility of emergent cells 
to cytolysis is a stable characteristic which is maintained in a  nonimmune  environment 
for  at  least  35  d  (more  than  70  population  doublings).  These  experiments  indicate 
that  antigenic  modulation  is  not  responsible  for  the  decreased  susceptibility  of 
emergent cells to CMC. 
Common  Target  Antigens  on  Original  and  Emergent  L5178Y  Cells.  The  decreased 
susceptibility  of emergent  L5178Y  cells to  CMC  could  be due  either  to  a  decreased 
expression  of a  common  target  antigen  or  to  a  decreased  expression  of a  different 
target  antigen  to  which  the  mouse  had  mounted  an  immune  response  during  the 
dormant  period.  To differentiate between these alternatives,  we attempted  to inhibit 
the  lysis of ~aCr-labeled  original  L5178Y  cells with  unlabeled  original  and  emergent 
L5178Y cells at several cell:cell ratios.  Normal DBA/2  thymocytes and  FLC-745 cells 
were used as potentially competing cells to control for nonspecific blocking due to cell 
crowding. 
As seen in Fig.  2, at a  25:1  ratio both unlabeled original and emergent cells almost 
completely inhibited lysis of the labeled cells. At a  5:1 ratio, a  discrimination could be 
made  between  the competitive activity of original  and  emergent  L5178Y  cells, with 
the emergent cells competing less actively than  the original cells. Little or no blocking 
occurred with either DBA/2  thymocytes or FLC-745 cells indicating that the observed 
competition  with  L5178Y  cells was  not  due  to cell crowding.  Because cold emergent 
cells competed  with labeled original cells for PC  lyric activity, we can conclude  that K.  J.  WEINHOLD,  D.  A.  MILLER,  AND  E.  F.  WHEELOCK  751 
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Fic.  2.  Inhibition of CMC  against SlCr-labeled original L5178Y cells by various numbers of 
original L5178Y (0), emergent L5178Y (A), FLC-745 (12]), or normal DBA/2 thymocytes (©). 
the emergent L5178Y cells share a common cytolytic target antigen with the original 
L5178Y  cells.  Moreover,  the  lower  competitive  activity  of emergent  L5178Y  cells 
suggested that  emergent cells express less of this common antigen  than  the original 
cells. 
Quantitative Expression of Tumor-Associated Antigens.  To determine whether the emer- 
gent L5178Y cells express lesser amounts of a common tumor associated antigen than 
the original cells, we quantitated  the expression of this antigen on both cell popula- 
tions. These experiments utilized an immune rabbit serum prepared against original 
L5178Y cells. This rabbit serum was first absorbed extensively with normal DBA/2 
thymocytes and a  DBA/2-derived, non-L5178Y, cross-reacting tumor cell line P815- 
X2. 
The first experiment performed with this absorbed rabbit serum tested the suscep- 
tibility  of the  original  and  emergent  L5178Y  cells  to complement-dependent  lysis. 
DBA/2 thymocytes were also used as a  control for the completeness of absorption of 
antibody to H-2  d antigens. As seen in Fig.  3, this serum lysed L5178Y cells, but not 
normal  DBA/2  thymocytes or  FLC-745  cells,  indicating  that  the  serum  contained 
antibodies  to L5178Y cell tumor-associated antigen  (TAA).  Emergent  L5178Y  cells 
were significantly less susceptible to lysis by this serum than  were original  L5178Y 
cells.  These experiments suggested that  emergent L5178Y cells displayed less target 
antigen than the original cells. However, because no definitive assessment of quanti- 
tative  differences  in  expression  of antigen  can  be  made  from  a  measurement  of 
cytolytic  susceptibility,  we  performed  an  antibody  absorption  experiment.  A  1:20 
dilution of Ra-a-L5178Y serum was absorbed with varying numbers of either original 
or emergent cells, and the amount ofcytolytic activity remaining after absorption was 
measured. As seen in Fig. 4, absorption of 50% of the cytolytic activity was achieved 
with  2.2  ×  106 original  L5178Y  cells and with  16.4  ×  106 emergent cells.  Normal 
DBA/2  thymocytes were unable  to absorb significant  amounts  of cytolytic activity 
from this serum.  Original  and emergent  L5178Y  cells have similar size ranges and 752  COMPARISON  OF  ORIGINAL  AND  EMERGENT  L5178Y  CELLS 
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FIG.  4.  Absorption of L5178Y cell cytolytic activity from rabbit anti-L5178Y  serum with varying 
numbers of original (0)  or emergent  (A) L5178Y cells, and with DBA/2 thymoeytes (O). The lines 
represent the cytolytic activity of the rabbit serum after absorption. 
surface morphologies (data not shown) and, therefore, have similar cell surface areas 
accessible to antibody attachment. These results indicate,  therefore, that on a popu- 
lation  basis,  emergent  cells  express  on  their  surface  less  TAA  that  is  accessible  to 
antibody than original L5178Y  cells. 
Heterogeneity  of Antigen  Expression  on  Original  and Emergent  L5178Y  Cells.  The  de- 
creased expression of TAA in the emergent L5178Y cell population may reflect either 
decreased antigen expression on all cells in the population or the existence of several 
tumor  cell  subpopulations,  with  each  subpopulation  expressing  amounts  of TAA 
ranging  from  zero  to  that  present  on  the  original  L5178Y  cells.  To  discriminate 
between these two possibilities, we performed indirect immunofluorescence assays on 
the original and emergent cell populations utilizing the rabbit anti-L5178Y  (original K. J.  WEINHOLD, D.  A.  MILLER, AND E.  F,  WHEELOCK 
TABLE IV 
Heterogeneity of Antigen Expression in Original and Emergent LS178 Y Cell Populations 
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Percent of cells displaying 0-4 +  immunofluorescence:[: 
Cell line* 
4+  3+  2+  1+  0 
L5178Y (Original)  --  80%  20%  --  -- 
L5178Y (Emergent)  --  20%  10%  65%  5% 
DBA/2 Thymocytes  ....  100% 
* Tumor cells were obtained from the appropriate mice (see text) and cultured for 3 d before assay. Normal 
DBA/2 cells were assayed directly after removal from mice. 
::1: Cells were reacted with a  1:40 dilution of rabbit anti-L5178Y (original) sera which had been extensively 
absorbed with normal DBA/2 tissues and with PS15X-2 tumor cells. After washing, the cells were stained 
with fluorescein-conjugated goat anti-rabbit serum. Slides were examined by using a single-blind method 
of evaluation. Fluorescent staining intensity was based upon the maximum (4 + ) staining of L5178Y ceils 
using a  1:40 dilution of nonabsorbed rabbit anti-LS178Y sera. 
cell)  sera employed in  the previous section. As seen in Table IV, both original and 
emergent L5178Y cell populations contained cells of mixed immunofluorescent inten- 
sities with greater variation present in the emergent cell population. 20% of emergent 
cells  stained  as  intensely  as  the  majority  of the  original  cells  and  ~  70%  of the 
emergent cells displayed less antigen than any of the original cells observed; 5% of the 
emergent cells displayed no detectable tumor antigen. Thus, the decreased suscepti- 
bility of emergent cells to CMC reflects a  mixed population of cells with most cells 
displaying less antigen than is present on the original cells. These emergent cells may 
have arisen from a subpopulation of the original L5178Y cells too small in number to 
be detected by immunofluorescence. 
Discussion 
In this report we describe various characteristics of tumor cells which grow out in 
L5178Y cell immunized and challenged mice following a prolonged period of clinical 
normalcy. We substantiate the presence of a true tumor dormant state in our L5178Y- 
DBA/2  model,  and  propose  a  mechanism  by  which  tumor  cells  avoid  immune 
cytolysis, persist in an immune environment, and eventually grow out to form overt 
tumors, We view tumor dormancy as a state in which tumor cells persist in a host for 
prolonged periods of time with little net growth and which is terminated by an event 
which permits their rapid outgrowth (I). Implicit in this definition is growth restraint 
imposed either by the host or by cells within the tumor population. The outgrowth of 
tumor cells at the end of tumor dormancy must be distinguished from outgrowth due 
either to new  transformation of host  cells during remission, or to slow growth of a 
subpopulation of the original primary tumor. Outgrowth due to recent transformation 
rather than recurrence of residual tumor is known to occur in strains of mice highly 
susceptible to virus-induced tumors such as leukemias and mammary adenocarcino- 
mas  (12),  and  has been  implicated  in  the relapse of human  leukemias  (13)  and  in 
Burkitt  lymphomas (7).  Prolonged clinical normalcy due to slow growth of residual 
tumor cells has been described  in experimental animal systems (14)  and in cases of 
clinical neoplasia, best illustrated with human breast cancer (15). 
In the present study, tumor cells which emerged at the end of the clinically normal 
period were identified by karyotype analysis as progeny of the L5178Y cells contained 
in  the  challenge  inoculum.  In  this  analysis,  female  derived  L5178Y  cells  were 754  COMPARISON  OF ORIGINAL AND EMERGENT L5178Y CELLS 
suppressed to a dormant state in male DBA/2 mice. Tumor cells emerging from male 
mice were shown to lack a Y chromosome. However, because host chromosomes may 
be deleted  after transformation  (16), a  more definitive analysis was required.  Using 
chromosome  banding  techniques,  we  demonstrated  that  nine  abnormal  marker 
chromosomes present  in original cells were also present  in the emergent cells.  Most 
abnormal chromosomes arise by unique events, and it would be extremely unlikely to 
have the same series of changes occur in two different tumors. In addition, both tumor 
lines had 70-80 chromosomes per cell, whereas diploid host cells had 40. 
Investigation of the possibility that  L5178Y  cells grew at  a  slow rate during  the 
dormant state was impeded by our inability to analyze directly the small numbers of 
tumor cells present  in  the  peritoneal  cavity during  dormancy.  However, we found 
that  cells  which  emerged  at  the  end  of dormancy  had  in  vivo growth  rates when 
passaged in  normal  mice, that  were equivalent  to the original  L5178Y  cells. These 
results implicate a slow net growth rate of tumor cells during the dormancy state, and 
a  dormancy-terminating event which converts the slow rate to a  rapid outgrowth of 
tumor cells. The observation that emergent L5178Y tumors, once detected at the end 
of the  tumor  dormant  period,  enlarge  more  rapidly  than  original  L5178Y  tumors 
growing in  nonimmunized  mice may reflect  a  loss of tumor suppressive activity in 
mice bearing emergent tumors. 
The L5178Y cells which grow out at the end of the dormant state were shown to be 
less susceptible to cell-mediated lysis by peritoneal effector cells obtained from L5178Y 
immunized  and  challenged  mice.  These  emergent  L5178Y  cells  may  have  been 
selected from the original L5178Y cell population by virtue of this decreased suscep- 
tibility to lysis. Immune-resistant tumor cells have been selected by exposing hetero- 
geneous populations to cytotoxic antiserum or immune cells in vitro (3)  and in vivo 
(2).  We have demonstrated, by indirect immunofluorescence (IFA), heterogeneity in 
antigen expression in both original and emergent cell populations with the majority 
of emergent  cells staining  less  intensely  than  most cells in  the original  population. 
This demonstrates that the decreased susceptibility of emergent cells is not due to the 
existence  of a  homogeneous  subpopulation.  There  is,  instead,  heterogeneity  with 
decreased expression of TAA on nearly all cells within the emergent cell population. 
Although no cells with such small expression of antigen were detected by IFA in the 
original population, the emergent cells may represent only a minute percentage of the 
original  population  with  amplification  of  the  immune  selected  cells  during  the 
emergent stage. 
Two other explanations of the decreased susceptibility of emergent L5178Y cells to 
CMC were considered in our system; antigenic modulation (17); and antigen masking 
(18). The role of antigenic modulation  in immune resistance in our tumor dormant 
system was ruled out by the demonstration that emergent cells did not reacquire full 
susceptibility  to  CMC  during  the  35  d  in  culture  in  a  nonimmune  environment. 
Antigen  masking has been  found  to affect the  expression of both  normal  (19)  and 
tumor-associated  surface  target  antigens  (20),  with  complement-dependent  lysis of 
susceptible cells  more greatly affected than  CMC  (I I).  In our system original  and 
emergent cells were equally susceptible both to alloimmune CMC and to complement- 
dependent lysis by anti-H-2  d and anti-Thy 1.2 sera indicating that masking of surface 
antigens on emergent cells is unlikely.  Strong evidence that TAA on emergent cells 
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that  neuraminidase  treatment  did  not  alter the susceptibility of emergent  cells  to 
CMC. 
The decreased susceptibility of  emergent L5178Y cells to lysis by cytolytic peritoneal 
effector T  cells could have been responsible for their emergence from a dormant state. 
However, we  reported earlier that  emergent  L5178Y cells fail to grow out  rapidly 
when inoculated back into tumor dormant mice (21). Thus, sufficient quantities of 
antigen must be present on the surface of emergent cells to serve as targets for tumor 
suppressive activity as long as such activity exists in the mouse. We demonstrated, by 
cold target  competition, a  common target  antigen  on  both original  and  emergent 
L5178Y cells. These experiments suggested that emergent cells may express decreased 
amounts of either a cytolytic target antigen or an accessory surface antigen necessary 
for  effector cell  recognition,  binding,  and  lysis  of tumor  cells.  Such  recognition 
antigens  may include products of the major histocompatibility complex (22),  fetal 
antigens (23), and virion-associated antigens (24). 
Quantitation of TAA expression on both original and emergent cells was performed 
with  rabbit  serum prepared against  original  L5178Y cells. This serum, extensively 
absorbed  with  DBA/2  tissues,  possessed  titrable  cytolytic activity against  L5178Y 
TAA. The observation that the susceptibilities of original and emergent cells to lysis 
by Ra-a-L5178Y serum paralleled their respective susceptibilities to CMC suggested 
that quantitative differences in expression of TAA may exist in these two populations. 
By measuring the ability of each population to absorb L5178Y cell lytic activity from 
Ra-a-L5178Y serum, we found that nearly eightfold more emergent cells than original 
cells were required to attain equal levels of absorption. This indicated that the original 
cell population displayed ~eightfold more of serologically detectable TAA than the 
emergent cell population. These results were comparable to those of Fenyo et al. who 
found that immune resistant YAC cells displayed roughly one-tenth the TAA of fully 
susceptible  cells  (2).  Biochemical analysis  of the  cell surface of the  YAC  cells  has 
shown altered expression of Moloney virus cell surface antigen (MCSA) and reduced 
amounts of gp71 and H-2 antigens (25). Cell surface analysis of original and emergent 
L5178Y cells  is  underway  in  our laboratory. Although  it  is  attractive to suggest  a 
correlation between the difference in expression of serologically detected TAA on the 
two populations of L5178Y cells and  their relative susceptibilities  to CMC,  such a 
conclusion is unwarranted until the serologic TAA is proven to be the target antigen 
for CMC. We have not been able, to date, to make this conclusion since Ra-a-L5178Y 
serum does not block lysis of L5178Y cells by effector PC (data not shown). 
Our working hypothesis for the persistence of L5178Y cells in a dormant state and 
for their eventual outgrowth is that L5178Y cells with decreased amounts of surface 
antigen are selected from a heterogeneous original L5178Y cell population during the 
tumor  dormant  state.  If the cells  are  selected early in  tumor dormancy when  the 
cytolytic immune response is at peak levels, their rapid outgrowth could be restrained 
by cytolytic or cytostatic effector cells.  However, as tumor suppressive activity wanes, 
the  L5178Y cells grow out  to form overt tumors. The decline in cytolytic immune 
responses may be the result of many factors (discussed in the previous communication). 
The present communication provides evidence that the decline in tumor suppressive 
activity may be due to a  decrease in  the immunogenicity of emergent  cells which 
results from decreased expression of TAA. Thus, emergence of tumor cells from the 
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amounts of TAA on its surface and decline in host tumor suppressive responses to a 
level which can no longer restrain  tumor outgrowth. If this hypothesis is correct, it 
should be possible to prolong the tumor dormant state or eradicate all dormant tumor 
cells  by stimulating host immune responses to them. Elucidation of the host mecha- 
nisms involved in control of the tumor dormant state in the murine model could thus 
serve  as  a  basis  for development  of effective prolongation or eradication  of tumor 
dormant states in man. 
Summary 
The tumor dormant state established in L5178Y immunized and challenged mice 
is characterized by a  prolonged period of clinical normalcy followed by rapid tumor 
outgrowth. The tumor cells  which emerged after termination of the tumor dormant 
state had abnormal marker chromosomes identical to those in the L5178Y cells  used 
in  the  original  challenge  inoculum, indicating that  the  emergent  tumor cells  were 
progeny of the challenge inoculum. Original and emergent L5178Y cells  had equiv- 
alent in vivo growth rates, when inoculated into normal DBA/2 mice. The emergent 
L5178Y cells were less susceptible than original cells to in vitro lysis by tumor dormant 
PC. Original and emergent L5178Y cells  expressed common tumor-associated target 
antigens  for cytolytic effector cells.  Both  modulation  and  masking  of these  target 
antigens were ruled out as mechanisms for decreased susceptibility to cell-mediated 
cytolysis.  Immunofluorescence revealed  heterogeneity  in  tumor-associated  antigen 
expression  within  both  original  and  emergent  cell  populations,  with  a  decreased 
intensity  of staining  in  the  emergent  population.  Both  populations  were  equally 
susceptible to lysis  by alloimmune cells,  alloantiserum, and anti-Thy  1.2 serum, but 
emergent cells  were less susceptible to lysis by serum directed against L5178Y TAA. 
Quantitative absorption revealed that the emergent L5178Y cells expressed eightfold 
less serologically detectable TAA than the original cells. These findings indicate that 
the  host  immune  response  developing during establishment  of the  tumor dormant 
state selects a stable tumor cell subpopulation which expresses decreased amounts of 
surface tumor-associated target antigens. 
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